Primary Image

generic image

Clinical Trial/Research Study

A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects

IRB Protocol Number STU00219033

Contact

nvg@sralab.org

Objective

This trial is no longer accepting applications.
For questions related to the trial, please contact Bing Chen at 312.238.7895.


This study is examining how the study drug, NVG-291, affects nerve connections in the spinal cord and whether it is safe and tolerable to use.

Volunteers in this study will:

  • Participate in study visits over 16 weeks.
  • Visits will take place at the Shirley Ryan 黑料网.

Visit involves:  

  • Non-invasive stimulation of the brain and spinal cord and startle acoustic stimuli.
  • Upper and lower limb training
  • Answer questionnaire
  • Physiological and physical assessments
  • Receiving daily injections of NVG-291 or placebo.

Who Can Participate

Participants with a spinal cord injury who are:

  • Between 18-75 years of age
  • Sustained a spinal cord injury at C1-C7 (20-90 days post injury)
  • In good physical health
  • Proficiency in English

Compensation

Participants will receive compensation.

Apply for this Trial

Your information will not be published.

All fields are required.

Featured Quote

More Studies

Help Improve Cognitive Testing for People with Spinal Cord Injury

This study aims to understand what adjustments help people with spinal cord injury take cognitive tests. Your input can help improve care and testing tools for others.

read more
view all

Latest Updates

view all